Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 6Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Endometrial Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Peritoneal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Platinum-resistant Recurrent Ovarian Cancer 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Pancreatic Ductal 1

Interventions

Carboplatin 2130-nm albumin-bound paclitaxel 2tremelimumab 1durvalumab 1cc-486 1amatuximab 1Oxaliplatin 1Leucovorin 1Gemcitabine 1Fluorouracil 1EC regimen 1Cisplatin 1CP protocol 1Azacitidine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Pancreatic Ductal × tremelimumab × Gynecologic × Clear all
NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

AstraZeneca

Phase 1 Completed
32 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡